Journal of Clinical Immunology

, Volume 32, Issue 4, pp 802–808 | Cite as

Type17 T-cells in Central Nervous System Autoimmunity and Tumors

Article

Abstract

Interleukin-17 (IL-17) producing Type17 T-cells, specifically T-helper (Th)17 cells reactive to central nervous system (CNS) autoantigens, manifest a higher migratory capability to the CNS parenchyma compared with other T-cell subpopulations due to their ability to penetrate the blood brain barrier (BBB). In the field of cancer immunotherapy, there are now a number of cell therapy approaches including early studies using T-cells transduced with chimeric antigen receptors in hematologic malignancy, suggesting that the use of T-cells or genetically modified T-cells could have a significant role in effective cancer therapy. However, the successful application of this strategy in solid tumors, such as CNS tumors, requires careful consideration of critical factors to improve the tumor-homing of T-cells. The current review is dedicated to discuss recent findings on the role of Type17 T-cells in CNS autoimmunity and cancer. The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors.

Keywords

Th17 IL-17 autoimmunity central nervous system multiple sclerosis gliomas adoptive transfer therapy 

Notes

Acknowledgments

Grant Support

2R01NS055140, 2P01 NS40923, 2P01 NS40923 and Musella Foundation for Brain Tumor Research and Information to HO. R01AI067472, AI058680 and the National Multiple Sclerosis Society RG3666 to S.J.K.

References

  1. 1.
    Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer[mdash]what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med. 2011;3:95ra73.PubMedCrossRefGoogle Scholar
  3. 3.
    Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med. 2006;354:758–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol.Google Scholar
  7. 7.
    Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1–13.PubMedCrossRefGoogle Scholar
  8. 8.
    El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010;5:189–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124:132–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol. 1981;127:1420–3.PubMedGoogle Scholar
  11. 11.
    Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157:3223–7.PubMedGoogle Scholar
  12. 12.
    Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–73.PubMedGoogle Scholar
  13. 13.
    Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Investig. 2009;119:61–9.PubMedGoogle Scholar
  14. 14.
    Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008;205:1535–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med. 2008;14:337–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Yamazaki T, Yang XO, Chung Y, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181:8391–401.PubMedGoogle Scholar
  20. 20.
    Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Kohler RE, Caon AC, Willenborg DO, et al. A role for macrophage inflammatory protein-3α/CC chemokine ligand 20 in immune priming during T cell-mediated inflammation of the central nervous system. J Immunol. 2003;170:6298–306.PubMedGoogle Scholar
  22. 22.
    Liston A, Kohler RE, Townley S, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol. 2009;182:3121–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Hedegaard CJ, Krakauer M, Bendtzen K, et al. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008;125:161–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain: J Neurol. 2009;132:3329–41.CrossRefGoogle Scholar
  26. 26.
    Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Abromson-Leeman S, Bronson RT, Dorf ME. Encephalitogenic T cells that stably express both T-bet and RORγt consistently produce IFNγ but have a spectrum of IL-17 profiles. J Neuroimmunol. 2009;215:10–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Suryani S, Sutton I. An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol. 2007;183:96–103.PubMedCrossRefGoogle Scholar
  29. 29.
    Murphy ÁC, Lalor SJ, Lynch MA, et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24:641–51.PubMedCrossRefGoogle Scholar
  30. 30.
    Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.PubMedCrossRefGoogle Scholar
  31. 31.
    Maniati E, Soper R, Hagemann T. Up for Mischief[quest] IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29:5653–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Wilke CM, Kryczek I, Wei S, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis. 2011;32:643–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Zou W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10:248–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 2010;11:674–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 2010;40:3312–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Martin-Orozco N, Chung Y, Chang SH, et al. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009;39:216–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Bending D, De La Peña H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Investig. 2009;119:565–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Nistala K, Adams S, Cambrook H, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci. 2010;107:14751–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114:596–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Martin-Orozco N, Muranski P, Chung Y, et al. T Helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787–98.PubMedCrossRefGoogle Scholar
  45. 45.
    Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci Transl Med. 2010;2:55ra78.PubMedCrossRefGoogle Scholar
  46. 46.
    Garcia-Hernandez MdlL, Hamada H, Reome JB, et al. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2010;184:4215–27.CrossRefGoogle Scholar
  47. 47.
    Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011Google Scholar
  48. 48.
    Hamai A, Pignon P, Raimbaud I, et al. Human Th17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ secreting cells as they differentiate into effector T cells in vivo. Canc Res. 2012Google Scholar
  49. 49.
    Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010;5:e15390.PubMedCrossRefGoogle Scholar
  50. 50.
    Cantini G, Pisati F, Mastropietro A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Canc Immunol Immunother. 2011;60:1739–50.CrossRefGoogle Scholar
  51. 51.
    Schwartzbaum JA, Huang K, Lawler S, et al. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology. 2010;12:320–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Hu J, Mao Y, Li M, et al. The profile of Th17 subset in glioma. Int Immunopharmacol. 2011;11:1173–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Zhou P, Sha H, Zhu J. The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res. 2010;38:611–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Brain Tumor ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Center for Neurologic Diseases, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  4. 4.American University of BeirutBeirutLebanon
  5. 5.Neurological Surgery, Surgery and Immunology, Clinical and Translational Science InstituteUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations